MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
Financing of $5.8 Million at a 25% premium will help advance the clinical development of MiNK-215, an armored-FAP-CAR-iNKT
GKCC, LLC joins as a new investor with Katie Chudnovsky appointed as a Board Observer
以25％的溢價融資580萬美元將有助於推進Armored-FAP-car-INKT mink-215的臨床開發
GKCC, LLC作爲新投資者加入，凱蒂·丘德諾夫斯基被任命爲董事會觀察員
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that it has entered into a stock purchase agreement to sell securities in a private placement financing (PIPE) for $5.8 million. This capital injection is earmarked for accelerating the clinical trials of MiNK-215, our leading allogeneic CAR-iNKT cell therapy targeting fibroblast activation protein (FAP) in solid tumors, which is planned to enter the clinic in early 2025.
紐約，2024年5月13日（GLOBE NEWSWIRE）——MinK Therapeutics, Inc.（納斯達克股票代碼：INKT）是一家臨床階段的生物製藥公司，率先發現、開發和商業化治療癌症和其他免疫介導疾病的異基因、現成不變自然殺傷劑 T（inkT）細胞療法，今天宣佈已簽訂股票購買協議，出售證券 580萬美元的私募融資（PIPE）。本次注資專門用於加速Mink-215的臨床試驗。Mink-215是我們領先的針對實體瘤成纖維細胞活化蛋白（FAP）的同種異體CAR-Inkt細胞療法，計劃於2025年初進入臨床。
"This funding will help advance our unique armored iNKT therapy MiNK-215," said Dr. Jennifer Buell, President and Chief Executive Officer at MiNK. "MiNK-215 is a novel cell therapeutic with the potential to overcome the limitations of traditional immune checkpoint inhibitors in solid tumors. Recent data highlighted MiNK-215's activity to eradicate tumor cells in a model of MSS colorectal cancer with metastatic liver disease, a critical and growing area of unmet need. We are excited to partner with GKCC and committed to advancing our mission of reshaping the cell therapy landscape."
MinK總裁兼首席執行官詹妮弗·比爾博士表示：“這筆資金將有助於推進我們獨特的裝甲InkT療法Mink-215。”“mink-215是一種新的細胞療法，有可能克服實體瘤中傳統免疫檢查點抑制劑的侷限性。最近的數據突顯了Mink-215在MSS結直腸癌合併轉移性肝病模型中根除腫瘤細胞的活性，這是一個需求未得到滿足的關鍵且不斷增長的領域。我們很高興與GKCC合作，並致力於推進我們重塑細胞療法格局的使命。”
In the PIPE, MiNK is selling 4,640,000 shares of its common stock at a price of $1.25 per share, a 25% premium. The PIPE is expected to close on May 14, 2024, subject to customary closing conditions.
在PIPE中，MinK將以每股1.25美元的價格出售其464萬股普通股，溢價25％。PIPE預計將於2024年5月14日關閉，但須遵守慣例成交條件。
In addition, MiNK is pleased to announce the appointment of Yekaterina ("Katie") Chudnovsky as Board Observer. An accomplished attorney and venture investor, Ms. Chudnovsky brings a wealth of experience as a dedicated patient advocate and supporter of medical research. She currently serves as the Chairperson of the GI Research Foundation (GIRF) at the University of Chicago Digestive Diseases Center, a role preceded by her 12-year tenure as President and Board Member. Additionally, Ms. Chudnovsky serves on the boards of Elicio Therapeutics, Immix Biopharma, XCures, and the Colorectal Cancer Alliance. She earned her BA from Northwestern University and a JD from DePaul University.
此外，MinK很高興地宣佈任命葉卡捷琳娜（“凱蒂”）丘德諾夫斯基爲董事會觀察員。丘德諾夫斯基女士是一位出色的律師和風險投資者，作爲一名專職的患者倡導者和醫學研究支持者，她擁有豐富的經驗。她目前擔任芝加哥大學消化系統疾病中心胃腸道研究基金會（GIRF）主席，此前她曾擔任主席兼董事會成員12年。此外，丘德諾夫斯基女士還在Elicio Therapeutics、Immix Biopharma、xCures和結直腸癌聯盟的董事會任職。她獲得了西北大學的文學學士學位和德保羅大學的法學博士學位。
About MiNK Therapeutics
關於 MinK Therapeut
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
MinK Therapeutics是一家處於臨床階段的生物製藥公司，開創了用於治療癌症和其他免疫介導疾病的異基因不變自然殺傷T（InkT）細胞療法的發現、開發和商業化。MinK正在推進原生和下一代工程InkT程序的管道，其平台旨在促進可擴展和可重複的製造，以實現現成交付。該公司總部位於紐約州紐約。欲了解更多信息，請訪問 https://minktherapeutics.com/ 或者 @MiNK_iNKT。可能對投資者很重要的信息將定期發佈在我們的網站和社交媒體渠道上。
Forward Looking Statements
前瞻性陳述
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic and curative potential of MiNK-215, including the mechanism of action, potency and safety, interim or top-line data, including statements regarding preclinical data, the anticipated benefits of MiNK-215 and clinical development plans and timelines. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K filed with the SEC. The securities described above have not been registered under the Securities Act of 1933, as amended. Accordingly, these securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
本新聞稿包含根據聯邦證券法安全港條款做出的前瞻性陳述，包括有關Mink-215治療和治療潛力的聲明，包括作用機制、效力和安全性、中期或主要數據，包括有關臨床前數據、Mink-215的預期益處以及臨床開發計劃和時間表的陳述。這些前瞻性陳述受風險和不確定性的影響，包括向美國證券交易委員會提交的最新10-K表中 “風險因素” 部分中描述的因素。上述證券尚未根據經修訂的1933年《證券法》進行註冊。因此，除非根據有效的註冊聲明或《證券法》註冊要求的適用豁免，否則不得在美國發行或出售這些證券。本新聞稿不應構成出售要約或徵求購買這些證券的要約，在根據任何此類司法管轄區的證券法進行註冊或獲得資格認證之前，在任何州或其他司法管轄區，此類要約、招標或出售是非法的，也不得出售這些證券。MinK提醒投資者不要過分依賴本新聞稿中包含的前瞻性陳述。這些聲明僅代表截至本新聞稿發佈之日，除法律要求外，MinK沒有義務更新或修改聲明。本警示性陳述對所有前瞻性陳述進行了明確的完整限定。
Investor Contact
投資者聯繫人
917-362-1370
917-362-1370
Media Contact
媒體聯繫人
781-674-4428
781-674-4428
Source: MiNK Therapeutics
來源：MinK Therapeutics
譯文內容由第三人軟體翻譯。